Aclaris Therapeutics (ACRS) Announces Two A-101 Phase 3s Met All Primary, Secondary Endpoints as SK Treatment
Tweet Send to a Friend
Aclaris Therapeutics, Inc. (Nasdaq: ACRS) announced that two pivotal Phase 3 trials of its lead product candidate A-101 40% Topical ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
